srpt gene therapy - Search News

Order byBest matchMost fresh

Children's Hospital LA Pauses Use of Sarepta Gene Therapy

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny

Shares of Sarepta Therapeutics SRPT are declining in the pre-market hours today after the announcement that it will voluntarily and temporarily halt all U.S. shipments of Elevidys, effective at the close of business today.

· 9h · on MSN

Sarepta to pause Elevidys gene therapy shipments in U.S.

· 2h

Sarepta falls after gene therapy maker pauses Elevidys shipments in US

· 2h

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

Sarepta Therapeutics was falling again in premarket trading Tuesday as its future looks increasingly shaky after it agreed to halt shipments of its Elevidys drug under pressure from the Food and Drug ...

STAT · 6h

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

· 1h

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Zacks Investment Research on MSN1d

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies. The company confirmed that a 51-year-old, non-ambulant (unable to walk) limb-girdle muscular dystrophy (LGMD) patient died due to acute liver failure (ALF).

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.